Studies of Small DNA Virus Encoded Oncogenes in Viral Carcinogenesis Using Laboratory Model Systems

Cancer is a devastating disease, presenting an immense disease burden to affected individuals and their families as well as health care systems with 10.9 million new cases and 6.7 million deaths per year. Approximately 12% of human cancers worldwide are caused by oncoviruses infection with more than 80% of cases occurring in the developing world.

Tumor viruses can be classified into two groups based on their genetic material;

1. DNA tumor viruses:

   1. Small DNA tumor viruses (Papilloma viruses, Polyoma viruses and adenoviruses).
   2. Complex DNA tumor viruses (Herpes viruses and Hepatitis B viruses).
2. RNA tumor viruses ( Hepatitis C viruses and human T-cell leukemia virus "HTLV").

There are around 100 types of HPV, with different variations in their genetic and oncogenic potential [5]. Thus, HPV genotypes are divided into 2 groups based on their vulnerability; High risk HPV (HR-HPV) and low risk HPV (LR-HPV).

The HPV genome encodes several oncoproteins [5]. E6 and E7 are the main genes responsible for cell transformation mediated by HR-HPV, and they modulate the activities of cellular proteins that regulate the cell cycle. Thus, the presence of E6/E7 can be a specific marker for diagnosing precancerous lesions by HPV.

Knowledge of the etiology of virus-mediated carcinogenesis, the networking of pathways involved in the transition from infection to cancer and the risk factors associated with each type of cancer, all suggest prophylactic and therapeutic strategies that may reduce the risk of virus-mediated cancer.

Study Overview

• Status: Unknown
• Conditions: DNA Virus Infections
• Intervention / Treatment: Genetic: HPV oncogenes

Detailed Description

Study subjects:

1. Inclusion criteria:

   • Age: 18 - 65 years old.
   • Women who are positive for HPV diagnosed by routine screening. Women willing to participate in the study and sign an informed consent

2. Exclusion criteria:

   • Age extremes (less than 18 years old or more than 65 years old).
   • Immuno-comprised patients, patients under steroid therapy or chemotherapy, or patients with serious medical illness that could affect their immune system.
   • Unknown medical history.

   Study Groups:

   • Group 1 (Cases): Patients known to have Cancer cervix with any degree of malignancy (diagnosed by routine screening or any other diagnostic tests)
   • Group 2 (Controls): Women sharing the same inclusion and exclusion criteria, but not known to have Cancer cervix

   Aim of The Study:

   1. Studying the role of HPV as an example of small DNA viruses in cell transformation and carcinogenesis.
   2. Determining the most HPV genotypes associated with high risks of cancer cervix occurrence.
   3. Detection of the HPV oncogenes playing role cell transformation and malignancy.

   4. Studying the role of viral DNA integration in cellular transformation and carcinogenesis.

      Study methods:

      Samples collection and storing:

      • Samples will be obtained from the cervix with the brush or swab\ by following the instructions corresponding to the type of collecting device.

      • Collection tubes will be stored at room temperature (15-30 °C).

      • Samples will be sent to the laboratory in less than 14 days following collection
      • The tubes can be preserved for 2-3 weeks at room temperature.

      HPV detection:

      • HPV cannot be propagated in tissue culture, and therefore, in most cases its accurate identification relies on molecular biology techniques, such as polymerase chain reaction (PCR).

      HPV Genotyping:

      • PCR-RFLP shows good discriminatory power by differentiating between HR and LR HPV genotypes, and it is possible to identify single or multiple infections .

      • In this technique, the amplified DNA is digested by restriction enzymes, resulting in DNA fragments of various lengths. Each fragment length is characteristic of a certain HPV genotype.

      • The commonest restriction enzymes are BamHI, Dd6eI, HaeIII, HinfI, PstI and RsaI.

      HPV Oncogenes and oncoproteins:

      • The main techniques used to detect mRNA for E6/E7 oncogenes are two commercial assays: PreTectW Proofer and APTIMAW HPV Assay. These techniques are based on transcription-mediated amplification of full-length E6/E7 transcripts using PCR.

      Statistical analysis:

      • Data will be analyzed by one-way analysis of variance using SPSS software version 24.0. Values will be expressed as mean ± S.D. For comparison between 2 groups, Student's t test will be used to determine whether the cases was significantly different from the control. Differences will be considered statistically significant at P<0.05, while P<0.01 will represent more significant change.

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Not Applicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Age: 18 - 65 years old.
• Women who are positive for HPV diagnosed by routine screening.
• Women willing to participate in the study and sign an informed consent

Exclusion Criteria:

• Age extremes (less than 18 years old or more than 65 years old).
• Immuno-comprised patients, patients under steroid therapy or chemotherapy, or patients with serious medical illness that could affect their immune system.
• Unknown medical history.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: BASIC_SCIENCE
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: SINGLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: cases; HPV detection HPV Genotyping HPV Oncogenes and oncoproteins	Genetic: HPV oncogenes; PCR and oncogenes detection
ACTIVE_COMPARATOR: control; HPV detection HPV Genotyping HPV Oncogenes and oncoproteins	Genetic: HPV oncogenes; PCR and oncogenes detection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
carcinogenesis	developing cancer cervix	6 months

Collaborators and Investigators

• Sponsor: Heba Momen kamel

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): September 1, 2017
• Primary Completion (ANTICIPATED): February 28, 2018
• Study Completion (ANTICIPATED): February 28, 2018

Study Registration Dates

• First Submitted: June 13, 2017
• First Submitted That Met QC Criteria: June 14, 2017
• First Posted (ACTUAL): June 15, 2017

Study Record Updates

• Last Update Posted (ACTUAL): June 15, 2017
• Last Update Submitted That Met QC Criteria: June 14, 2017
• Last Verified: June 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Virus Diseases; Infections; Neoplasms; Neoplastic Processes; Carcinogenesis; DNA Virus Infections
• Other Study ID Numbers: 17200086

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No